Extracorporeal Immunoglobulin Elimination for the Treatment of Severe Myasthenia Gravis

<table>AChRA levels in patient no. 3. <svg height="10.325" id="M16" style="vertical-align:-0.0pt" version="1.1" viewbox="0 0 13.4125 10.325" width="13.4125" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,10.325)">
<g transform="translate(72,-63.74)">
<text transform="matrix(1,0,0,-1,-71.95,63.79)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑋</tspan>
</text>
</g>
</g>
</svg> axis: Procedure = numeral order of procedures from the start of therapy; <svg height="10.325" id="M17" style="vertical-align:-0.0pt" version="1.1" viewbox="0 0 11.6125 10.325" width="11.6125" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,10.325)">
<g transform="translate(72,-63.74)">
<text transform="matrix(1,0,0,-1,-71.95,63.79)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝑌</tspan>
</text>
</g>
</g>
</svg> axis = AChRA levels in ng/L. Normal value in our laboratory = 0.00–0.40 nmol/L.</table>

BioMed Research International

fig3

Figure 3

Figure 3: Extracorporeal Immunoglobulin Elimination for the Treatment of Severe Myasthenia Gravis 